Qualigen warns of going‑concern risk amid cash crunch, Marizyme exposure and dilution

Snapshot - Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Short take: the company is burning cash, has raised short-term financing to survive, slowed R&D to conserve cash, and carries material going-concern risk. Key balance-sheet items, recent financings and reserves (Marizyme notes) are driving headline volatility and potential dilution.

Key metrics & facts
* Cash and cash equivalents: $331,601 (June 30, 2025).
* Total assets: $3,962,673; Total liabilities (current): $5,614,956; Stockholders' deficit: $(1,652,283).
* Accumulated deficit: $(127,393,162).
* Short-term notes receivable (net): $3,312,496 (gross Marizyme notes $4,140,496; allowance for credit losses $828,000).
* Promissory notes (current liabilities): $3,474,667; Convertible debt: $142,069; Warrant liabilities: $213,976.
* Net loss - three months ended June 30, 2025: $(1,685,417); six months: $(4,331,588).
* EPS (basic & diluted): $(1.00) for the quarter; $(2.76) for six months. Weighted-average shares: 1,683,881 (Q) / 1,570,925 (6M).
* Operating cash flow (6 months): net cash used $2,687,507; Financing provided $3,363,000; Net change in cash: $(843,007).
* Management flagged "substantial doubt" about going concern for 12 months following issuance of these statements.

Income statement - positives
* R&D cut dramatically: R&D expense fell to $17,815 for the quarter and $50,982 for six months - management intentionally slowed development to conserve cash.
* Non‑cash gains: marked gains on fair‑value changes (warrants / convertible note) provided small income offsets in the period (e.g., $37,874 gain on convertible debt in Q2).
* Interest income recognized on Marizyme notes: $140,433 (Q) / $251,303 (6M), reflecting yield on those advances (18% contractual rate).

Income statement - negatives
* Continued losses and wide operating burn: total expenses remained high due to General & Administrative - $1.395M (Q) and $3.889M (6M).
* Credit loss provision: $271,000 (Q) / $468,000 (6M) against Marizyme notes raises collection risk on that receivable.
* No revenue line items - the business remains early-stage/clinical and dependent on financing or partnerships.
* Heavy dilution risk: debt/convertible instruments, Series A preferred conversions, and multiple warrants create near-term dilution potential (see weighted-average share increase versus prior periods).
* Large non-recurring IR / investor-relations spend: ~$1.5M in H1 paid to IR Agency LLC (not expected to recur but increased near-term G&A by ~34% of operating expenses H1).

What's happening inside the company
* Cash conservation: management slowed QN-302 and Pan‑RAS development in Q2 to reduce spend.
* Funding activity: H1 2025 saw short-term borrowings and a $220k convertible note (fair-value accounting loss on issuance). From Jan-July 2025 the company borrowed ~$3.64M; in July 2025 it closed a private placement raising ~$4.258M (subsequent event).
* Marizyme exposure: Qualigen advanced ~$3.776M to Marizyme (Marizyme Notes) and recognized accrued interest and an allowance - recovery depends on Marizyme's ability to perform or be acquired.
* Governance / controls: management disclosed material weaknesses in accounting staffing and ITGCs; remediation deferred until additional funding is available.
* Liability-profile change: new promissory notes include steep penalty/premium terms (subsequent amendments add ~30% premium on some short-term notes), increasing future cash obligations.

Risks to monitor (near term)
* Liquidity / going concern - cash ~$332k at 6/30/25, operating burn continues; planned financings are critical.
* Marizyme collectability - $828k allowance suggests meaningful credit risk; write-offs would hit earnings/cash recoveries.
* Dilution from preferred, convertible notes and warrants - conversions already occurred and more remain possible, reducing common equity value.
* Legal and contingent liabilities - placement-agent lawsuit (LifeSci) and promissory-note penalties could materialize.
* Controls weakness - increases risk of misstated results until remediated.

Bottom line
Qualigen (NASDAQ: QLGN) is executing emergency capital and cost measures to survive. The income statement shows success cutting R&D and realizing some non‑cash gains, but that is overwhelmed by continued operating losses, a credit loss reserve on Marizyme exposure, high G&A (including one‑time IR spending), heavy short‑term liabilities and dilution risk. The company's near-term viability depends on additional financing or strategic transactions; investors should watch cash runway, Marizyme recoverability, promissory note terms, and any new equity raises.

Source: Qualigen Therapeutics, Inc. Form 10‑Q for quarter ended June 30, 2025 (filed Aug 14, 2025).